In a recent exploratory analysis of the PROTECT cohort study, researchers sought to determine the prognostic value of mild elevations in cardiac troponin levels in patients with hemodynamically stable pulmonary embolism (PE). Specifically, they compared the results of conventional cardiac troponin I (cTnI) tests with high-sensitivity cardiac troponin I (hs-cTnI) tests to evaluate their predictive
Health
In recent interviews with scientists and company executives, there has been a renewed interest in the development of vaccines to treat Alzheimer’s disease. This is an exciting development, as the search for an effective treatment for this debilitating condition has been ongoing for many years. While there have been setbacks in the past, researchers are
In a recent phase III randomized study, the use of apixaban (Eliquis) as prophylaxis did not decrease the rate of venous thromboembolism (VTE) in children newly diagnosed with acute lymphoblastic leukemia or lymphoma. The findings from the PREVAPIX-ALL study, conducted by Sarah H. O’Brien, MD, and colleagues, indicate that apixaban did not demonstrate significant benefits
The United States is facing an alarming crisis of opioid overdoses, with high-potency synthetic opioids like fentanyl and metonitazene wreaking havoc across the nation. Medication-assisted treatment (MAT) has proven to be a life-saving intervention for individuals with opioid use disorder (OUD), offering unmatched success in patient outcomes. MAT typically involves treatment with FDA approved medications,
When considering a career in medicine, there are numerous factors to weigh, including personal passions, desired work hours, and financial considerations. However, I firmly believe that the most significant consideration should be the type of patients a physician will care for throughout their career. As a pediatric neurosurgeon, I have dedicated my medical career to
The recent evaluation of gefapixant for the treatment of chronic cough by the FDA’s Pulmonary-Allergy Drugs Advisory Committee has raised concerns over its efficacy. The committee concluded that the evidence presented does not warrant approval for this condition, for which there is currently no approved therapy available. Although phase III trials showed some reduction in
Recent warnings about the presence of lead in recalled applesauce packets have raised concerns among pediatricians. While it is still uncertain whether children exposed to these packets have suffered from acute lead poisoning, experts emphasize the importance of taking these warnings seriously. High blood lead levels in young children can lead to clinical diseases, particularly
The Senate Finance Healthcare Subcommittee hearing on making certain telehealth rules permanent for the Medicare program revealed a rare display of discord among panelists. While the senators present were united in their belief that the current flexible rules for telehealth should be made permanent for Medicare beneficiaries, the discussions among the panelists themselves sparked a
Bayer recently announced its decision to withdraw its follicular lymphoma drug, copanlisib (Aliqopa), from the U.S. market. This move comes after the drug failed a confirmatory study, known as CHRONOS-4, and discussions with the FDA. The phase III study was required as a condition for the PI3K inhibitor’s accelerated approval. The study aimed to evaluate
In recent clinical trials, the investigational drug lebrikizumab has shown promising results in the treatment of moderate-to-severe atopic dermatitis (AD). This interleukin (IL)-13 inhibitor has demonstrated both clinical efficacy and the ability to allow patients to space out their treatments. Despite the anticipation of approval from the FDA, recent issues at a manufacturing facility have